research Topical 2% Tofacitinib for Children with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis
Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
Search
for
Sort by
Research
30 / 1000+ results 
research Efficacy of Topical Tofacitinib in Promoting Hair Growth in Non-Scarring Alopecia: Possible Mechanism via VEGF Induction
Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
research Topical Tofacitinib Solution for the Treatment of Alopecia Areata Affecting Eyelashes
A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
research Topical Tofacitinib for the Treatment of Alopecia Areata Affecting Facial Hair
Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib
Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
research Topical Tofacitinib for Patients with Lichen Planopilaris and/or Frontal Fibrosing Alopecia
Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
research Efficacy and Safety of Topical Tofacitinib for the Treatment of Alopecia Areata
Topical tofacitinib is effective and safe for treating alopecia areata.
research Treatment of Refractory Folliculitis Decalvans With the Topical JAK Inhibitor Tofacitinib
Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
research Treatment of Longstanding Alopecia Areata Universalis of the Eyebrows/Facial Hair with Oral and Topical Tofacitinib
Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.
research Efficacy of Topical Tofacitinib in Promoting Hair Growth in Non-Scarring Alopecia
Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.
research Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates
A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research A Pilot Study of 2% Tofacitinib Cream with Narrowband Ultraviolet B for the Treatment of Facial Vitiligo
Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.
research Nanostructured Lipid Carriers Promote Percutaneous Absorption and Hair Follicle Targeting of Tofacitinib for Treating Alopecia Areata
Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata
Topical JAK inhibitors may help children with alopecia areata regrow hair.
research Topical SCD-153, A 4-Methyl Itaconate Prodrug, For The Treatment Of Alopecia Areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
research Effect of Tofacitinib on the Expression of Noggin/BMP-4 and Hair Growth Stimulation in Mice
Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
research Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review
Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
research Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research Monotherapy for Alopecia Areata: A Systematic Review and Network Meta-Analysis
Intralesional corticosteroids work best for mild alopecia areata, and DPCP works best for moderate to severe cases.
research Fzd2 Controls Multiple Aspects of Epidermal Development Through Distinct Signaling Mechanisms
Fzd2 is important for skin and hair development through various signaling ways.
research Rare Presentation of Concomitant Alopecia Areata and Vitiligo in a Teenager
A teenager had both alopecia areata and vitiligo, which are rare to occur together.
research JAK Inhibitors in Dermatology: The Promise of a New Drug Class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research New Drugs Under Investigation for the Treatment of Alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Janus Kinase Inhibitors for Alopecia Areata: A Narrative Review
Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children
Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
research Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.